Literature DB >> 11024147

A new primary effusion lymphoma-derived cell line yields a highly infectious Kaposi's sarcoma herpesvirus-containing supernatant.

J S Cannon1, D Ciufo, A L Hawkins, C A Griffin, M J Borowitz, G S Hayward, R F Ambinder.   

Abstract

A primary effusion lymphoma (PEL) cell line, JSC-1, that yields highly infectious Kaposi's sarcoma herpesvirus (KSHV) supernatants was established from the ascitic fluid of a human immunodeficiency virus-positive patient. Flow cytometry showed strong expression of CD45 and lambda light-chain restriction. Southern blot hybridization showed immunoglobulin heavy-chain gene rearrangements in the tumor and the resultant cell line consistent with B-cell lineage. Expression of viral genes was assessed by reverse transcription-PCR and immunohistochemistry. Only latent Epstein-Barr virus (EBV) gene expression was detected, and this was at a low level. In contrast, lytic and latent KSHV gene expression were detected. Tetradecanoyl phorbol acetate and butyrate upregulated KSHV lytic expression, but not EBV lytic expression. Viral supernatant from JSC-1 was much more efficient at infecting primary human dermal microvascular endothelial cells (DMVECs) with KSHV than supernatants from BC-3 or BCP-1 PEL cell lines. Quantitation of viral yields produced by the PEL lines showed at least 2 orders of magnitude more DNase I-resistant KSHV DNA in the JSC-1 supernatant compared to BC-3 or BCP-1 supernatants. KSHV infection in DMVECs was associated with a change from a cobblestone to a spindle shape, LANA expression, and an increased number of mitoses.

Entities:  

Mesh:

Year:  2000        PMID: 11024147      PMCID: PMC102057          DOI: 10.1128/jvi.74.21.10187-10193.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate.

Authors:  J Luka; B Kallin; G Klein
Journal:  Virology       Date:  1979-04-15       Impact factor: 3.616

2.  Epstein-Barr virus in AIDS-related primary central nervous system lymphoma.

Authors:  E M MacMahon; J D Glass; S D Hayward; R B Mann; P S Becker; P Charache; J C McArthur; R F Ambinder
Journal:  Lancet       Date:  1991-10-19       Impact factor: 79.321

3.  Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines.

Authors:  K Takada
Journal:  Int J Cancer       Date:  1984-01-15       Impact factor: 7.396

4.  Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8.

Authors:  A V Moses; K N Fish; R Ruhl; P P Smith; J G Strussenberg; L Zhu; B Chandran; J A Nelson
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.

Authors:  J Sample; L Young; B Martin; T Chatman; E Kieff; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

6.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

7.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

8.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.

Authors:  Y Chang; E Cesarman; M S Pessin; F Lee; J Culpepper; D M Knowles; P S Moore
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

9.  Transcription of BamHI-A region of the EBV genome in NPC tissues and B cells.

Authors:  H L Chen; M M Lung; J S Sham; D T Choy; B E Griffin; M H Ng
Journal:  Virology       Date:  1992-11       Impact factor: 3.616

10.  Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.

Authors:  E M Deacon; G Pallesen; G Niedobitek; J Crocker; L Brooks; A B Rickinson; L S Young
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  105 in total

1.  Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein.

Authors:  O Brad Spiller; Mairi Robinson; Elizabeth O'Donnell; Steven Milligan; B Paul Morgan; Andrew J Davison; David J Blackbourn
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in activation of the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic-cycle replication-associated protein (RAP) promoter in cooperation with the KSHV replication and transcription activator (RTA) and RAP.

Authors:  Shizhen Emily Wang; Frederick Y Wu; Masahiro Fujimuro; Jianchao Zong; S Diane Hayward; Gary S Hayward
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi's sarcoma.

Authors:  Brian R Lane; Jianguo Liu; Paul J Bock; Dominique Schols; Michael J Coffey; Robert M Strieter; Peter J Polverini; David M Markovitz
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures.

Authors:  D M Ciufo; J S Cannon; L J Poole; F Y Wu; P Murray; R F Ambinder; G S Hayward
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 5.  Split genes and their expression in Kaposi's sarcoma-associated herpesvirus.

Authors:  Zhi-Ming Zheng
Journal:  Rev Med Virol       Date:  2003 May-Jun       Impact factor: 6.989

6.  Host range of Kaposi's sarcoma-associated herpesvirus in cultured cells.

Authors:  Jill T Bechtel; Yuying Liang; Joshua Hvidding; Don Ganem
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

7.  Lytic replication-associated protein (RAP) encoded by Kaposi sarcoma-associated herpesvirus causes p21CIP-1-mediated G1 cell cycle arrest through CCAAT/enhancer-binding protein-alpha.

Authors:  Frederick Y Wu; Qi-Qun Tang; Honglin Chen; Colette ApRhys; Christopher Farrell; Jianmeng Chen; Masahiro Fujimuro; M Daniel Lane; Gary S Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-26       Impact factor: 11.205

Review 8.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

9.  Kaposi's sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jkappa, the major downstream effector of the Notch signaling pathway.

Authors:  Ke Lan; Daniel A Kuppers; Erle S Robertson
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

10.  Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects.

Authors:  C Liu; Y Okruzhnov; H Li; J Nicholas
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.